These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 16288937

  • 21. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.
    Son J, Lee SB, Lee DW, Kim IY, Lee SJ, Lee SM, Song SH, Seong EY, Kwak IS.
    Clin Exp Nephrol; 2013 Apr; 17(2):275-83. PubMed ID: 22990301
    [Abstract] [Full Text] [Related]

  • 22. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients.
    Fabbiani M, Di Giambenedetto S, Sali M, Farina S, Sansonetti P, Tamburrini E, Dal Verme LZ, Delogu G, De Luca A, Kelvin D, Cauda R, Fadda G.
    Vaccine; 2011 Apr 05; 29(16):2836-9. PubMed ID: 21349364
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 05; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 24. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun 05; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 25. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY, Song JY, Choi WS, Lee J, Seo YB, Kwon YJ, Ko GJ, Cha DR, Kang YS, Lee YK, Cheong HJ, Kim WJ.
    Hum Vaccin Immunother; 2016 Nov 05; 12(11):2902-2908. PubMed ID: 27802078
    [Abstract] [Full Text] [Related]

  • 26. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 05; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 27. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

  • 29. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 02; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 30. The immunogenicity of intradermal influenza vaccination in COPD patients.
    Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra KN.
    Vaccine; 2010 May 28; 28(24):4045-51. PubMed ID: 20412877
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
    Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.
    Pediatrics; 2010 Oct 28; 126(4):e762-70. PubMed ID: 20819892
    [Abstract] [Full Text] [Related]

  • 32. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 28; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 33. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M.
    Gerontology; 2007 Jul 28; 53(6):411-8. PubMed ID: 17975317
    [Abstract] [Full Text] [Related]

  • 34. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O.
    Ann Rheum Dis; 2008 Jul 28; 67(7):937-41. PubMed ID: 17981914
    [Abstract] [Full Text] [Related]

  • 35. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.
    Arthritis Rheum; 2010 Jan 28; 62(1):75-81. PubMed ID: 20039396
    [Abstract] [Full Text] [Related]

  • 36. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly.
    Martin JT.
    Biologicals; 1997 Jun 28; 25(2):209-13. PubMed ID: 9236054
    [Abstract] [Full Text] [Related]

  • 37. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study.
    Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.
    Rheumatology (Oxford); 2009 Oct 28; 48(10):1294-9. PubMed ID: 19692457
    [Abstract] [Full Text] [Related]

  • 38. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.
    Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D.
    Vaccine; 2004 Dec 02; 23(3):283-9. PubMed ID: 15530669
    [Abstract] [Full Text] [Related]

  • 39. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM.
    Vaccine; 2005 Jul 08; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [Abstract] [Full Text] [Related]

  • 40. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, Tel F, Prunotto G, Serra D, Galeone C, Plebani A, Principi N.
    Vaccine; 2011 Feb 11; 29(8):1677-82. PubMed ID: 21199699
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.